As an inhibitor, Etanercept competitively binds to soluble and membrane-bound TNF to inhibit its activity, exhibiting high binding capacity (Ki = 10-10M), which has effective relief of inflammation, and now is used to treat severely active AS, psoriasis, juvenile idiopathic arthritis, especially moderately or severely active RA (169). This evidence concerns the gene TNF and rheumatoid arthritis.